Acquisition Opportunity Healix Infusion Therapy Inc has been acquired by Singlepoint Healthcare as of June 16, 2026, signaling a potential shift in strategic priorities, integration opportunities, and cross-sell potential within a broader national infusion services platform.

Strategic Partnerships Historically, Healix pursued partnerships with WeInfuse and DoseMe, indicating openness to software and decision-support collaborations; this suggests potential for reselling or co-developing infusion workflow, dosing, or IT integrations with potential buyers or partners.

Tech Enablement Existing tech stack includes security certification (CompTIA Security+), content platforms, workflow software, and enterprise web/infrastructure tools, presenting an opportunity to upsell security, compliance, and IT services to modernize infusion center IT environments.

Revenue Focus Current revenue range is in the $25M–$50M band with a lean workforce (11–50 employees), which may indicate scale-up needs for scalable software adoption, managed services, and automation solutions to support growth post-acquisition.

Market Positioning Positioned as a national infusion services provider for physician offices and ambulatory centers, creating sales angles around integrated infusion management platforms, outsourcing of specialized therapies, and comprehensive compliance-enabled service offerings to incumbents and new market entrants.